Fig. 2From: Outcomes and safety of concomitant topiramate or metformin for antipsychotics-induced obesity: a randomized-controlled trialITT analyses showed change in weight (a), BMI (b), and W–H ratio (c) during treatment: compared with baseline: *P < 0.05, **P < 0.001; with metformin: #P < 0.05, ##P < 0.01Back to article page